NYSE:GMRE - Global Medical REIT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.50
  • Forecasted Upside: -1.27 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$15.70
▼ -0.2 (-1.26%)
1 month | 3 months | 12 months
Get New Global Medical REIT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMRE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMRE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.50
▼ -1.27% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Global Medical REIT in the last 3 months. The average price target is $15.50, with a high forecast of $18.00 and a low forecast of $13.00. The average price target represents a -1.27% upside from the last price of $15.70.

Buy

The current consensus among 4 polled investment analysts is to buy stock in Global Medical REIT. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021B. RileyBoost Price TargetBuy$16.00 ➝ $18.00Low
i
4/16/2021BMO Capital MarketsInitiated CoverageOutperform$16.00Medium
i
9/1/2020Stifel NicolausReiterated RatingBuy$15.00High
i
7/1/2020Berenberg BankInitiated CoverageBuy$13.00Medium
i
3/18/2020B. RileyUpgradeNeutral ➝ Buy$16.00 ➝ $12.00High
i
Rating by B. Maher at B. Riley
3/6/2020Robert W. BairdBoost Price TargetOutperform$14.00 ➝ $17.00Medium
i
3/6/2020B. RileyDowngradeBuy ➝ Neutral$15.00 ➝ $16.00High
i
Rating by Bryan Maher at B. Riley
3/5/2020Stifel NicolausBoost Price TargetBuy$14.00 ➝ $16.00High
i
2/7/2020National SecuritiesInitiated CoverageBuy$16.00Low
i
1/7/2020Janney Montgomery ScottUpgradeNeutral ➝ Buy$14.50Medium
i
12/20/2019B. RileyBoost Price TargetBuy$13.00 ➝ $15.00Medium
i
12/17/2019Stifel NicolausBoost Price TargetBuy$12.00 ➝ $14.00Low
i
5/10/2019Boenning ScattergoodReiterated RatingBuy$11.00High
i
Rating by Merrill Ross at Boenning Scattergood
4/15/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$11.00Medium
i
3/8/2019B. RileySet Price TargetBuy$11.00High
i
Rating by Bryan Maher at B. Riley
3/7/2019Boenning ScattergoodReiterated RatingBuyMedium
i
Rating by M. Ross at Boenning Scattergood
12/19/2018Janney Montgomery ScottDowngradeBuy ➝ Neutral$9.03High
i
11/12/2018B. RileyReiterated RatingBuyLow
i
Rating by B. Maher at B. Riley
11/7/2018Boenning ScattergoodUpgradeNeutral ➝ Buy$11.00Low
i
Rating by Merrill Ross at Boenning Scattergood
10/11/2018Robert W. BairdInitiated CoverageOutperform$11.00Medium
i
8/10/2018B. RileySet Price TargetBuy$11.00Medium
i
Rating by Bryan Maher at B. Riley
8/9/2018Boenning ScattergoodReiterated RatingHoldMedium
i
Rating by Merrill Ross at Boenning Scattergood
6/29/2018Boenning ScattergoodReiterated RatingNeutralLow
i
Rating by M. Ross at Boenning Scattergood
5/10/2018B. RileyLower Price TargetBuy ➝ Buy$10.50 ➝ $10.00High
i
Rating by Bryan Maher at B. Riley
3/28/2018DA DavidsonUpgradeNeutral ➝ Buy$8.00High
i
Rating by B. Oxford at DA Davidson
3/8/2018B. RileyReiterated RatingBuyLow
i
Rating by Bryan Maher at B. Riley
3/7/2018Cantor FitzgeraldInitiated CoverageBuy$12.00High
i
11/10/2017B. RileyReiterated RatingBuy$10.50N/A
i
Rating by B. Maher at B. Riley
11/1/2017B. RileyReiterated RatingBuyN/A
i
Rating by B. Maher at B. Riley
9/18/2017(FBRC)Reiterated RatingBuy$10.00 ➝ $10.50High
i
Rating by C. Kucera at (FBRC)
9/1/2017Cantor FitzgeraldReiterated RatingOverweight$12.00Medium
i
Rating by J. France at Cantor Fitzgerald
8/22/2017DA DavidsonDowngradeBuy ➝ Neutral$11.00 ➝ $10.00High
i
Rating by Barry Oxford at DA Davidson
7/11/2017(FBRC)Reiterated RatingOutperform$10.00Low
i
Rating by C. Kucera at (FBRC)
3/28/2017Compass PointUpgradeNeutral ➝ BuyMedium
i
2/23/2017Janney Montgomery ScottInitiated CoverageBuyN/A
i
11/10/2016DA DavidsonSet Price TargetBuy$12.00N/A
i
Rating by Barry Oxford at DA Davidson
11/10/2016WunderlichDowngradeBuy ➝ HoldN/A
i
Rating by Craig Kucera at Wunderlich
9/20/2016Compass PointDowngradeBuy ➝ NeutralN/A
i
Rating by Steven Shaw at Compass Point
7/26/2016DA DavidsonInitiated CoverageBuy$12.00N/A
i
7/25/2016DA DavidsonReiterated RatingBuyN/A
i
Rating by B. Oxford at DA Davidson
7/25/2016OppenheimerInitiated CoverageOutperform$12.00N/A
i
7/11/2016Truist FinancialInitiated CoverageHold$10.50N/A
i
7/11/2016WunderlichInitiated CoverageBuy$11.75N/A
i
7/11/2016Compass PointInitiated CoverageBuy$12.00N/A
i
(Data available from 6/16/2016 forward)
Global Medical REIT logo
Global Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.
Read More

Today's Range

Now: $15.70
$15.68
$15.98

50 Day Range

MA: $14.40
$13.51
$15.90

52 Week Range

Now: $15.70
$10.01
$15.98

Volume

763,403 shs

Average Volume

494,690 shs

Market Capitalization

$954.47 million

P/E Ratio

N/A

Dividend Yield

5.16%

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Medical REIT?

The following equities research analysts have issued stock ratings on Global Medical REIT in the last year: B. Riley, Berenberg Bank, BMO Capital Markets, Stifel Nicolaus, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for GMRE.

What is the current price target for Global Medical REIT?

4 Wall Street analysts have set twelve-month price targets for Global Medical REIT in the last year. Their average twelve-month price target is $15.50, suggesting a possible downside of 1.3%. B. Riley has the highest price target set, predicting GMRE will reach $18.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $13.00 for Global Medical REIT in the next year.
View the latest price targets for GMRE.

What is the current consensus analyst rating for Global Medical REIT?

Global Medical REIT currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GMRE will outperform the market and that investors should add to their positions of Global Medical REIT.
View the latest ratings for GMRE.

What other companies compete with Global Medical REIT?

How do I contact Global Medical REIT's investor relations team?

Global Medical REIT's physical mailing address is 2 Bethesda Metro Center Suite 440, BETHESDA MD, 20814. The company's listed phone number is 202-524-6851 and its investor relations email address is [email protected] The official website for Global Medical REIT is www.globalmedicalreit.com.